Radalbuvir

Drug Profile

Radalbuvir

Alternative Names: GS-9669

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases
  • Class Amides; Antivirals; Carboxylic acids; Cyclohexanes; Cyclohexenes; Small molecules; Thiophenes
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Puerto Rico (PO, Tablet)
  • 01 Jul 2014 Gilead completes a phase II trial for Hepatitis C (in combination with ledipasvir/sofosbuvir; Treatment-naive; Treatment-experienced) in USA (NCT01984294)
  • 01 Dec 2013 Gilead Sciences completes the ELECTRON phase IIb trial in Hepatitis C (combination therapy, treatment-naive) in New Zealand (NCT01260350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top